Cipla is currently trading at Rs. 894.85, up by 11.90 points or 1.35% from its previous closing of Rs. 882.95 on the BSE.
The scrip opened at Rs. 890.20 and has touched a high and low of Rs. 896.00 and Rs. 877.70 respectively. So far 264748 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 966.00 on 20-Apr-2021 and a 52 week low of Rs. 565.90 on 15-May-2020.
Last one week high and low of the scrip stood at Rs. 924.00 and Rs. 869.55 respectively. The current market cap of the company is Rs. 71936.86 crore.
The promoters holding in the company stood at 36.73%, while Institutions and Non-Institutions held 40.43% and 22.84% respectively.
Cipla has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company, USA for the manufacture and commercialization of the drug baricitinib for Covid-19 indication. Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
This collaboration is a step further in Cipla’s efforts to enhance access to critical treatments for patients affected by the pandemic. Cipla will leverage its extensive distribution footprint to make this therapy accessible to more patients and markets.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1483.75 |
| Dr. Reddys Lab | 5947.30 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 958.90 |
| Lupin | 1580.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
